Canada Spends Logo

Explore our Budget 2026 analysis

Program directory · Patented Medicine Prices Review Board Canada

Patented Medicine Price Monitoring Program

Program code
BYU02 (PMPRB)
Core responsibility
Monitor Patented Medicine Prices
In Departmental Plans
2025-26 – 2026-27 · New since an earlier plan

What it does

In accordance with the Patent Act, PMPRB Staff reviews the price at which rights holders sell their patented medicines in Canada to identify instances where it recommends that the Chairperson issue a Notice of Hearing on the price of that medicine. The Chairperson then may decide whether to issue said Notice of Hearing. At the hearing, an impartial panel composed of Board members hears all the evidence from the parties and analyzes it in light of the factors set out in section 85 of the Act. If the Hearing Panel concludes that the price of a patented medicine is/was excessive in any market in Canada, it can order the maximum ceiling price to be reduced to a non-excessive level. It can also order a rights holder to make a payment to the Government of Canada to offset the excess revenues earned and can double the amount of this payment if there has been a policy of excessive pricing.

The main source of evidence used to assess whether a hearing should be held is the price information filed by rights holders with the PMPRB in accordance with the requirements and timing set out in the Patented Medicine Regulations. Specifically, rights holders file Canadian and foreign price information every six months for every dosage form and strength of every patented medicine they sell in Canada. This represents thousands of individual price filings. Timely review of these filings is at the heart the effective fulfilment of the PMPRB’s price monitoring mandate.

Source: the department's Program Inventory, via GC InfoBase.

History and lineage

First appears in the Departmental Plans in 2025-26. The data does not record when a program was created; it may be older than its first appearance here, which is limited by the sources (program spending starts in 2010-11, Departmental Plans in 2018-19).

2018-192019-202020-212021-222022-232023-242024-252025-262026-272027-282028-29Patented Medicine Price Regulation Program 2018-19: $5.7MPatented Medicine Price Regulation Program 2019-20: $7.7MPatented Medicine Price Regulation Program 2020-21: $8.9MPatented Medicine Price Regulation Program 2021-22: $7.3MPatented Medicine Price Regulation Program 2022-23: $6.9MPatented Medicine Price Regulation Program 2023-24: $7.9MPatented Medicine Price Regulation Program 2024-25: $7.6MPatented Medicine Price Regulation Program 2025-26: $12.1MPatented Medicine Price Regulation Program 2026-27: $12.1MPatented Medicine Price Monitoring Program 2025-26: $12.3MPatented Medicine Price Monitoring Program 2026-27: $11.3MPatented Medicine Price Monitoring Program 2027-28: $11MPatented Medicine Price Monitoring Program 2028-29: $10.7MPatented Medicine Price Regulation ProgramPatented Medicine Price Monitoring Program
Bars: spending by fiscal year (dark: actual; light: actual restated on the 2017-18 program structure; outlined: the latest plan's forecast; grey: related programs). Bands: each program in the lineage over the years it has data.
ProgramRelationYears with dataActual spending over those years
Patented Medicine Price Regulation ProgramEarlier program (name match, medium confidence)2018-19 – 2026-27$52.1M
Patented Medicine Price Monitoring ProgramThis program2025-26 – 2028-29—

Significant changes in scope and budget

Detected from the data: renames between plans, programs it appears to replace, merge with or split into (matched by name), year-over-year changes in spending of at least 25% and $5M, or in employees of at least 20% and 25 FTEs, linked budget measures, and results indicators added or dropped.

YearWhat changedSource
2025-26Appears to replace Patented Medicine Price Regulation ProgramCanada Spends name match across plans (an inference)

Success criteria

The program's indicators from its department's Departmental Results Framework: the target set in each year's plan, and the result reported the following year. Source: GC InfoBase.

Historical: targets against results

No results reported yet.

Current: the 2026-27 plan's targets

Percentage of rights holder filings monitored within the calendar year
Expected result: Timely and effective monitoring of price information provided by rights holders
95%2026-27

Bars: result reported. Dashed line: target.

Report yearTargetDueResultStatus
2026-27≥ 95%2027—Planned

Future goals: targets due after 2026-27

Percentage of Hearings completed within 24 months of the issuance of a Notice of Hearing
Expected result: Timely and effective monitoring of price information provided by rights holders
90%2026-27

Bars: result reported. Dashed line: target.

Report yearTargetDueResultStatus
2026-27≥ 90%2028—Planned

Spending and employees: planned against actual

Spending

2025-26: $12.3M2025-262026-27: $11.3M2026-272027-28: $11M2027-282028-29: $10.7M2028-29
Outlined bar: planned in that year's Departmental Plan (dashed: the latest plan, for years not yet reported). Filled bar: actual.
Show the numbers
Fiscal yearPlannedActual
2025-26$12.3M—
2026-27$11.3M—
2027-28$11M*—
2028-29$10.7M*—

Employees (FTEs)

2025-26: 432025-262026-27: 432026-272027-28: 432027-282028-29: 432028-29
Outlined bar: planned in that year's Departmental Plan (dashed: the latest plan, for years not yet reported). Filled bar: actual.
Show the numbers
Fiscal yearPlannedActual
2025-2643—
2026-2743—
2027-2843*—
2028-2943*—

Planned spending, plan by plan

Each row is one year's Departmental Plan and its forecast for the next three fiscal years; read a column down to see how the forecast for one year changed. The last row is what was actually spent. Click an amount for its source. Biggest changes in federal spending plans

Plan2025-262026-272027-282028-29
2025-26 plan$12,285,557$12,297,976$12,297,976
2026-27 plan$11,303,616$11,039,666$10,739,217
Actual

Actual spending is from Departmental Results Reports and the Public Accounts, as published in GC InfoBase. FTEs are full-time equivalents.